Liu Xinhui, Liu Siqi, Luo Denggui, Huang Shiying, Wang Fochang, Zhang Bing, Chen Yulian, Zheng Lin, Lu Jiandong, Li Shunmin
Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China.
Shenzhen Key Laboratory of Hospital Chinese Medicine Preparation, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China.
Front Pharmacol. 2021 Feb 2;11:622658. doi: 10.3389/fphar.2020.622658. eCollection 2020.
Jian-Pi-Yi-Shen formula (JPYSF) is a traditional Chinese medicine (TCM) formula used in clinic to treat chronic kidney disease (CKD) for decades. However, the mechanisms of JPYSF in treating CKD have not been fully elucidated. The aim of the present study was to test the renoprotective effect of JPYSF on CKD rat model and investigate the potential mechanism from the perspective of serum exosomal microRNAs (miRNAs). CKD rat model was induced by feeding Sprague-Dawley rats a diet containing 0.75% adenine for four weeks. The rats in the treatment group were given 10.89 g/kg JPYSF by gavage every day, starting from the 3rd week of the adenine-containing diet for six weeks. Serum biochemistry and histopathology were used to evaluate the renoprotective effects of JPYSF. Serum exosomes were isolated by ExoQuick-TC PLUS exosomes extraction kit and were identified by transmission electron microscopy, nanoparticle tracking analysis, and western blot. Exosomal miRNAs profiling was analyzed by small RNA sequencing. The results showed that JPYSF treatment significantly lowered serum creatinine and blood urea nitrogen levels and alleviated renal pathological injury in CKD rats. Furthermore, serum exosomes were successfully isolated and identified. Small RNA sequencing revealed that 4 exosomal miRNAs (miR-192-5p, miR-194-5p, miR-802-5p, and miR-143-3p) were significantly downregulated in the CKD group and were markedly upregulated after JPYSF treatment. At last, miR-192-5p was identified as the most relevant miRNA for CKD diagnosis and JPYSF treatment. In conclusion, JPYSF protects kidney from adenine-induced CKD, which may be associated with modulation of exosomal miRNAs.
健脾益肾方(JPYSF)是一种在临床上用于治疗慢性肾脏病(CKD)数十年的中药方剂。然而,JPYSF治疗CKD的机制尚未完全阐明。本研究的目的是测试JPYSF对CKD大鼠模型的肾脏保护作用,并从血清外泌体微小RNA(miRNA)的角度探讨其潜在机制。通过给Sprague-Dawley大鼠喂食含0.75%腺嘌呤的饲料四周来诱导建立CKD大鼠模型。治疗组大鼠从含腺嘌呤饲料喂养的第3周开始,每天经口灌胃给予10.89 g/kg JPYSF,持续六周。采用血清生化和组织病理学方法评估JPYSF的肾脏保护作用。使用ExoQuick-TC PLUS外泌体提取试剂盒分离血清外泌体,并通过透射电子显微镜、纳米颗粒跟踪分析和蛋白质免疫印迹法进行鉴定。通过小RNA测序分析外泌体miRNA谱。结果显示,JPYSF治疗显著降低了CKD大鼠的血清肌酐和血尿素氮水平,并减轻了肾脏病理损伤。此外,成功分离并鉴定了血清外泌体。小RNA测序显示,4种外泌体miRNA(miR-192-5p、miR-194-5p、miR-802-5p和miR-143-3p)在CKD组中显著下调,JPYSF治疗后明显上调。最后,miR-192-5p被确定为与CKD诊断和JPYSF治疗最相关的miRNA。总之,JPYSF可保护肾脏免受腺嘌呤诱导的CKD损伤,这可能与外泌体miRNA的调节有关。